AG-120 Racemate is primarily used in cancer research, particularly in the study of targeted therapies for certain types of leukemia and solid tumors. It functions as an inhibitor of mutant isocitrate dehydrogenase 1 (IDH1), an enzyme that is abnormally active in some cancers and contributes to the accumulation of oncometabolites that disrupt normal cellular differentiation. By blocking the activity of mutant IDH1, AG-120 Racemate helps restore normal cell differentiation pathways, reducing tumor growth and promoting cancer cell maturation. It is commonly used in preclinical studies to evaluate the efficacy and mechanism of IDH1 inhibition, supporting the development of more effective treatments for IDH1-mutant cancers. Its role as a racemate also allows researchers to compare the biological activity of individual enantiomers during drug optimization.